
Acute Pain Market
Description
Acute Pain Market Report and Forecast 2024-2032
The acute pain market was valued at USD 72.6 billion in 2023, driven by the rising cases of acute pain-related conditions across the 8 major markets. The market is expected to grow at a CAGR of 4.2% during the forecast period 2024-2032, reaching a market value of USD 105.1 billion by 2032.
Acute Pain Market Analysis
Acute pain is a sudden onset of discomfort or pain, often resulting from injury, surgery, or medical conditions such as infections or inflammation. It typically lasts for a short duration, ranging from hours to weeks, and subsides with appropriate treatment or healing of the underlying condition. Acute pain serves as a protective mechanism, alerting the body to injury, and can be effectively managed through various treatments, including analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and anaesthetics, depending on the cause and severity of the pain.
Market Drivers
The acute pain market is rapidly evolving, propelled by the changing treatment approaches. As ongoing research uncovers new insights into the disease, several significant trends are emerging, shaping the future trajectory of this market.
Acute Pain Market Segmentation
Market Breakup by Drug Class
Market Breakup by Form
Market Breakup Indication
Market Breakup by Distribution Channel
Market Breakup by Region
Acute Pain Market Competitive Landscape
The competitive landscape of the acute pain market includes major players such as Pfizer Inc., Abbott, GSK plc, Novartis AG, Purdue Pharma LP, Sun Pharmaceutical, Eli Lilly and Company, Intas Pharma, Johnson & Johnson Services Inc., and Sanofi. These companies are actively developing innovative pain management solutions, with a strong focus on non-opioid alternatives. Strategic partnerships, research investments, and clinical trials are key strategies employed by these players to strengthen their positions and expand market reach.
Key Questions Answered in the Report
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the acute pain market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in acute pain.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the acute pain industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
The acute pain market was valued at USD 72.6 billion in 2023, driven by the rising cases of acute pain-related conditions across the 8 major markets. The market is expected to grow at a CAGR of 4.2% during the forecast period 2024-2032, reaching a market value of USD 105.1 billion by 2032.
Acute Pain Market Analysis
Acute pain is a sudden onset of discomfort or pain, often resulting from injury, surgery, or medical conditions such as infections or inflammation. It typically lasts for a short duration, ranging from hours to weeks, and subsides with appropriate treatment or healing of the underlying condition. Acute pain serves as a protective mechanism, alerting the body to injury, and can be effectively managed through various treatments, including analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and anaesthetics, depending on the cause and severity of the pain.
Market Drivers
- Rising Surgical Procedures: The increasing number of surgical procedures globally is contributing to a higher prevalence of postoperative acute pain, driving demand for pain management therapies and medications in hospitals and outpatient settings.
- Growing Incidence of Acute Injuries: A rise in sports injuries, accidents, and trauma cases is fuelling the demand for effective acute pain management solutions, especially in orthopaedic and emergency care.
- Advances in Pain Management Medications: The development of innovative pain management medications, such as longer-acting analgesics and new formulations of NSAIDs, is improving patient outcomes and driving market growth.
- Increasing Awareness of Pain Management: Growing awareness among healthcare professionals and patients about the importance of managing acute pain effectively is boosting the adoption of pain relief therapies and improving patient quality of life.
- Risk of Opioid Addiction: The widespread use of opioids for acute pain management poses a significant risk of addiction, making it a major challenge for healthcare providers to balance pain relief with the risk of dependency.
- Side Effects of Pain Medications: Many pain medications, including NSAIDs and opioids, are associated with adverse side effects such as gastrointestinal issues, nausea, and drowsiness, leading to limited patient adherence and treatment challenges.
- Under-treatment of Acute Pain: Despite advancements in pain management, acute pain is often under-treated, particularly in developing regions where access to appropriate medications and healthcare professionals is limited.
- Regulatory Restrictions on Opioids: Increasing regulations and restrictions on opioid prescriptions, due to the opioid crisis in many countries, are limiting the use of these drugs, thereby challenging the treatment of severe acute pain.
- Lack of Awareness in Low-Income Regions: In many low-income regions, awareness about acute pain management is still limited, resulting in inadequate treatment and prolonged suffering for patients with acute injuries or postoperative pain.
- Development of Non-Opioid Alternatives: There is significant potential for the development of non-opioid alternatives, such as novel NSAIDs, topical analgesics, and anaesthetics, offering safer options for acute pain management without the risk of addiction.
- Focus on Personalised Pain Management: Advances in personalised medicine, including genetic profiling, are enabling tailored pain management strategies that cater to individual patient needs, offering more effective and targeted acute pain relief.
- Telemedicine and Remote Pain Management: The rise of telemedicine presents opportunities for managing acute pain remotely, especially for patients recovering from surgery or injuries at home, enabling better access to pain management consultations and follow-up care.
- Innovations in Drug Delivery Systems: The development of advanced drug delivery systems, such as transdermal patches and extended-release formulations, offers more convenient and effective ways to manage acute pain, improving patient compliance and outcomes.
The acute pain market is rapidly evolving, propelled by the changing treatment approaches. As ongoing research uncovers new insights into the disease, several significant trends are emerging, shaping the future trajectory of this market.
- Growing Preference for NSAIDs Over Opioids
- Increased Demand for Multimodal Pain Management
- Rising Use of Topical Analgesics
- Technological Advancements in Pain Monitoring
- Focus on Patient-Centric Pain Management
- Expansion of Online Pharmacies for Pain Medications
Acute Pain Market Segmentation
Market Breakup by Drug Class
- NSAIDs
- Anesthetics
- Anticonvulsants
- Anti-migraine Agents
- Antidepressants
- Analgesics
- Others
Market Breakup by Form
- Oral
- Parenteral
- Topical
- Others
Market Breakup Indication
- Arthritic Pain
- Neuropathic Pain
- Postoperative Pain
- Muscle Sprain/Strain
- Bone Fracture
- Acute Appendicitis
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Independent Pharmacies
- Online Pharmacies
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Acute Pain Market Competitive Landscape
The competitive landscape of the acute pain market includes major players such as Pfizer Inc., Abbott, GSK plc, Novartis AG, Purdue Pharma LP, Sun Pharmaceutical, Eli Lilly and Company, Intas Pharma, Johnson & Johnson Services Inc., and Sanofi. These companies are actively developing innovative pain management solutions, with a strong focus on non-opioid alternatives. Strategic partnerships, research investments, and clinical trials are key strategies employed by these players to strengthen their positions and expand market reach.
Key Questions Answered in the Report
- How are advancements in pain monitoring technologies impacting the management of acute pain?
- What challenges are associated with opioid use in acute pain management, and how is the market addressing these issues?
- How is the increasing preference for non-opioid alternatives influencing treatment strategies in the acute pain market?
- What role do emerging markets play in shaping the future of the acute pain market?
- How are technological innovations in drug delivery systems improving patient outcomes in acute pain management?
- What is the impact of multimodal pain management on the treatment landscape for acute pain?
- How are online pharmacies transforming the distribution of acute pain medications?
- What opportunities exist for pharmaceutical companies to develop personalised acute pain management therapies?
- Which regions are expected to witness the highest growth in the acute pain market, and why?
- How are key players like Pfizer and Novartis driving innovation through clinical trials and product development?
- What are the major trends shaping the future of pain management in postoperative and trauma care settings?
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the acute pain market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in acute pain.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the acute pain industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Acute Pain Market Overview – 8 Major Markets
- 3.1 Acute Pain Market Historical Value (2017-2023)
- 3.2 Acute Pain Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Acute Pain Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Acute Pain Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 U.S.
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU-4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 U.S.
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU-4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment seeking rate, by Country
- 7.1.3.1 U.S.
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU-4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Acute Pain Market Landscape – 8 Major Markets
- 8.1 Acute Pain Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Acute Pain Market: Product Landscape
- 8.2.1 Analysis by Drug Class
- 8.2.2 Analysis by Form
- 8.2.3 Analysis by Indication
- 9 Acute Pain Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Acute Pain Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Acute Pain Market Segmentation (2018-2034) - 8 Major Markets
- 12.1 Acute Pain Market (2018-2034) by Drug Class
- 12.1.1 Market Overview
- 12.1.2 NSAIDs
- 12.1.3 Anesthetics
- 12.1.4 Anticonvulsants
- 12.1.5 Anti-migraine Agents
- 12.1.6 Antidepressants
- 12.1.7 Analgesics
- 12.1.8 Others
- 12.2 Acute Pain Market (2018-2034) by Form
- 12.2.1 Market Overview
- 12.2.2 Oral
- 12.2.3 Parenteral
- 12.2.4 Topical
- 12.2.5 Others
- 12.3 Acute Pain Market (2018-2034) Indication
- 12.3.1 Market Overview
- 12.3.2 Arthritic Pain
- 12.3.3 Neuropathic Pain
- 12.3.4 Postoperative Pain
- 12.3.5 Muscle Sprain/Strain
- 12.3.6 Bone Fracture
- 12.3.7 Acute Appendicitis
- 12.3.8 Others
- 12.4 Acute Pain Market (2018-2034) by Distribution Channel
- 12.4.1 Market Overview
- 12.4.2 Hospital Pharmacies
- 12.4.3 Independent Pharmacies
- 12.4.4 Online Pharmacies
- 12.4.5 Others
- 12.5 Acute Pain Market (2018-2034) by Region
- 12.5.1 Market Overview
- 12.5.2 United States
- 12.5.3 EU-4 and the United Kingdom
- 12.5.3.1 Germany
- 12.5.3.2 France
- 12.5.3.3 Italy
- 12.5.3.4 Spain
- 12.5.3.5 United Kingdom
- 12.5.4 India
- 12.5.5 Japan
- 13 United States Acute Pain Market (2018-2034)
- 13.1 United States Acute Pain Market Historical Value (2017-2023)
- 13.2 United States Acute Pain Market Forecast Value (2024-2032)
- 13.3 United States Acute Pain Market (2018-2034) by Drug Class
- 13.3.1 Market Overview
- 13.3.2 NSAIDs
- 13.3.3 Anesthetics
- 13.3.4 Anticonvulsants
- 13.3.5 Anti-migraine Agents
- 13.3.6 Antidepressants
- 13.3.7 Analgesics
- 13.3.8 Others
- 13.4 United States Acute Pain Market (2018-2034) by Form
- 13.4.1 Market Overview
- 13.4.2 Oral
- 13.4.3 Parenteral
- 13.4.4 Topical
- 13.4.5 Others
- 13.5 United States Acute Pain Market (2018-2034) Indication
- 13.5.1 Market Overview
- 13.5.2 Arthritic Pain
- 13.5.3 Neuropathic Pain
- 13.5.4 Postoperative Pain
- 13.5.5 Muscle Sprain/Strain
- 13.5.6 Bone Fracture
- 13.5.7 Acute Appendicitis
- 13.5.8 Others
- 13.6 United States Acute Pain Market (2018-2034) by Distribution Channel
- 13.6.1 Market Overview
- 13.6.2 Hospital Pharmacies
- 13.6.3 Independent Pharmacies
- 13.6.4 Online Pharmacies
- 13.6.5 Others
- 14 EU-4 and United Kingdom Acute Pain Market (2018-2034)
- 14.1 EU-4 and United Kingdom Acute Pain Market Historical Value (2017-2023)
- 14.2 EU-4 and United Kingdom Acute Pain Market Forecast Value (2024-2032)
- 14.3 EU-4 and United Kingdom Acute Pain Market (2018-2034) by Drug Class
- 14.3.1 Market Overview
- 14.3.2 NSAIDs
- 14.3.3 Anesthetics
- 14.3.4 Anticonvulsants
- 14.3.5 Anti-migraine Agents
- 14.3.6 Antidepressants
- 14.3.7 Analgesics
- 14.3.8 Others
- 14.4 EU-4 and United Kingdom Acute Pain Market (2018-2034) by Form
- 14.4.1 Market Overview
- 14.4.2 Oral
- 14.4.3 Parenteral
- 14.4.4 Topical
- 14.4.5 Others
- 14.5 EU-4 and United Kingdom Acute Pain Market (2018-2034) Indication
- 14.5.1 Market Overview
- 14.5.2 Arthritic Pain
- 14.5.3 Neuropathic Pain
- 14.5.4 Postoperative Pain
- 14.5.5 Muscle Sprain/Strain
- 14.5.6 Bone Fracture
- 14.5.7 Acute Appendicitis
- 14.5.8 Others
- 14.6 EU-4 and United Kingdom Acute Pain Market (2018-2034) by Distribution Channel
- 14.6.1 Market Overview
- 14.6.2 Hospital Pharmacies
- 14.6.3 Independent Pharmacies
- 14.6.4 Online Pharmacies
- 14.6.5 Others
- 15 India Acute Pain Market
- 15.1 India Acute Pain Market Historical Value (2017-2023)
- 15.2 India Acute Pain Market Forecast Value (2024-2032)
- 15.3 India Acute Pain Market (2018-2034) by Drug Class
- 15.3.1 Market Overview
- 15.3.2 NSAIDs
- 15.3.3 Anesthetics
- 15.3.4 Anticonvulsants
- 15.3.5 Anti-migraine Agents
- 15.3.6 Antidepressants
- 15.3.7 Analgesics
- 15.3.8 Others
- 15.4 India Acute Pain Market (2018-2034) by Form
- 15.4.1 Market Overview
- 15.4.2 Oral
- 15.4.3 Parenteral
- 15.4.4 Topical
- 15.4.5 Others
- 15.5 India Acute Pain Market (2018-2034) Indication
- 15.5.1 Market Overview
- 15.5.2 Arthritic Pain
- 15.5.3 Neuropathic Pain
- 15.5.4 Postoperative Pain
- 15.5.5 Muscle Sprain/Strain
- 15.5.6 Bone Fracture
- 15.5.7 Acute Appendicitis
- 15.5.8 Others
- 15.6 India Acute Pain Market (2018-2034) by Distribution Channel
- 15.6.1 Market Overview
- 15.6.2 Hospital Pharmacies
- 15.6.3 Independent Pharmacies
- 15.6.4 Online Pharmacies
- 15.6.5 Others
- 16 Japan Acute Pain Market
- 16.1 Japan Acute Pain Market Historical Value (2017-2023)
- 16.2 Japan Acute Pain Market Forecast Value (2024-2032)
- 16.3 Japan Acute Pain Market (2018-2034) by Drug Class
- 16.3.1 Market Overview
- 16.3.2 NSAIDs
- 16.3.3 Anesthetics
- 16.3.4 Anticonvulsants
- 16.3.5 Anti-migraine Agents
- 16.3.6 Antidepressants
- 16.3.7 Analgesics
- 16.3.8 Others
- 16.4 Japan Acute Pain Market (2018-2034) by Form
- 16.4.1 Market Overview
- 16.4.2 Oral
- 16.4.3 Parenteral
- 16.4.4 Topical
- 16.4.5 Others
- 16.5 Japan Acute Pain Market (2018-2034) Indication
- 16.5.1 Market Overview
- 16.5.2 Arthritic Pain
- 16.5.3 Neuropathic Pain
- 16.5.4 Postoperative Pain
- 16.5.5 Muscle Sprain/Strain
- 16.5.6 Bone Fracture
- 16.5.7 Acute Appendicitis
- 16.5.8 Others
- 16.6 Japan Acute Pain Market (2018-2034) by Distribution Channel
- 16.6.1 Market Overview
- 16.6.2 Hospital Pharmacies
- 16.6.3 Independent Pharmacies
- 16.6.4 Online Pharmacies
- 16.6.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 India CDSCO
- 17.5 Japan PMDA
- 18 Patent Analysis
- 18.1 Analysis by Drug Class of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Grants Analysis
- 19.1 Analysis by Year
- 19.2 Analysis by Amount Awarded
- 19.3 Analysis by Issuing Authority
- 19.4 Analysis by Grant Distribution Channel
- 19.5 Analysis by Funding Institute
- 19.6 Analysis by NIH Departments
- 19.7 Analysis by Recipient Organization
- 20 Clinical Trials Analysis
- 20.1 Analysis by Trial Registration Year
- 20.2 Analysis by Trial Status
- 20.3 Analysis by Trial Phase
- 20.4 Analysis by Therapeutic Area
- 20.5 Analysis by Geography
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Drug Class of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Drug Class of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 Pfizer Inc.
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Development
- 23.2.5 Certifications
- 23.3 Abbott
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Development
- 23.3.5 Certifications
- 23.4 GSK plc
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Development
- 23.4.5 Certifications
- 23.5 Novartis AG
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Development
- 23.5.5 Certifications
- 23.6 Purdue Pharma LP
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Development
- 23.6.5 Certifications
- 23.7 Sun Pharmaceutical
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Company News and Development
- 23.7.5 Certifications
- 23.8 Eli Lily and Company
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Company News and Development
- 23.8.5 Certifications
- 23.9 Intas Pharma
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Company News and Development
- 23.9.5 Certifications
- 23.10 Johnson & Johnson Services Inc.
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Company News and Development
- 23.10.5 Certifications
- 23.11 Sanofi
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Company News and Development
- 23.11.5 Certifications
- 24 Acute Pain Treatment Drugs - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- *The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.